Cyclin Dependent Kinase 9 Inhibitors for Cancer Therapy

Cyclin dependent kinase (CDK) inhibitors have been the topic of intense research for nearly 2 decades due to their widely varied and critical functions within the cell. Recently CDK9 has emerged as a druggable target for the development of cancer therapeutics. CDK9 plays a crucial role in transcription regulation; specifically, CDK9 mediated transcriptional regulation of short-lived antiapoptotic proteins is critical for the survival of transformed cells. Focused chemical libraries based on a plethora of scaffolds have resulted in mixed success with regard to the development of selective CDK9 inhibitors. Here we review the regulation of CDK9, its cellular functions, and common core structures used to target CDK9, along with their selectivity profile and efficacy in vitro and in vivo.

[1]  J. Wood,et al.  TG02, a novel oral multi-kinase inhibitor of CDKs, JAK2 and FLT3 with potent anti-leukemic properties , 2012, Leukemia.

[2]  R. Gaynor,et al.  A Novel CDK9 Inhibitor Shows Potent Antitumor Efficacy in Preclinical Hematologic Tumor Models , 2014, Molecular Cancer Therapeutics.

[3]  P. Dent,et al.  Bortezomib and flavopiridol interact synergistically to induce apoptosis in chronic myeloid leukemia cells resistant to imatinib mesylate through both Bcr/Abl-dependent and -independent mechanisms. , 2004, Blood.

[4]  N. Munshi,et al.  Preclinical activity of P276-00, a novel small-molecule cyclin-dependent kinase inhibitor in the therapy of multiple myeloma , 2009, Leukemia.

[5]  M Ladetto,et al.  AT7519, A novel small molecule multi-cyclin-dependent kinase inhibitor, induces apoptosis in multiple myeloma via GSK-3β activation and RNA polymerase II inhibition , 2010, Oncogene.

[6]  Laurent Meijer,et al.  Meridianins, a new family of protein kinase inhibitors isolated from the ascidian Aplidium meridianum. , 2004, Bioorganic & medicinal chemistry letters.

[7]  Agnieszka K. Witkiewicz,et al.  The history and future of targeting cyclin-dependent kinases in cancer therapy , 2015, Nature Reviews Drug Discovery.

[8]  M. Berk,et al.  The role of lamotrigine in the management of bipolar disorder , 2007, Neuropsychiatric disease and treatment.

[9]  Stephen P. Hale,et al.  The exploration of macrocycles for drug discovery — an underexploited structural class , 2008, Nature Reviews Drug Discovery.

[10]  C. H. Herrmann,et al.  Differential localization and expression of the Cdk9 42k and 55k isoforms , 2005, Journal of cellular physiology.

[11]  J. Ladias,et al.  Crystal structure of human cyclin K, a positive regulator of cyclin-dependent kinase 9. , 2007, Journal of molecular biology.

[12]  B. N. Devaiah,et al.  Cross-talk Among RNA Polymerase II Kinases Modulates C-terminal Domain Phosphorylation* , 2012, The Journal of Biological Chemistry.

[13]  R. Garofalo,et al.  CDK9-Dependent Transcriptional Elongation in the Innate Interferon-Stimulated Gene Response to Respiratory Syncytial Virus Infection in Airway Epithelial Cells , 2013, Journal of Virology.

[14]  P. Stiegler,et al.  Activation of MyoD-dependent transcription by cdk9/cyclin T2 , 2002, Oncogene.

[15]  N. Pryer,et al.  Specific inhibition of cyclin-dependent kinase 4/6 by PD 0332991 and associated antitumor activity in human tumor xenografts. , 2004, Molecular cancer therapeutics.

[16]  B. Peterlin,et al.  7SK snRNA: a noncoding RNA that plays a major role in regulating eukaryotic transcription , 2012, Wiley interdisciplinary reviews. RNA.

[17]  S. Fesik,et al.  ‘Seed’ analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737 , 2007, Oncogene.

[18]  W. Parker.  Enzymology of purine and pyrimidine antimetabolites used in the treatment of cancer. , 2009, Chemical reviews.

[19]  T. Kawasaki,et al.  Simple indole alkaloids and those with a nonrearranged monoterpenoid unit. , 2005, Natural product reports.

[20]  P. Dent,et al.  Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation. , 2007, Cancer research.

[21]  E. Estey,et al.  Randomized phase II study of two schedules of flavopiridol given as timed sequential therapy with cytosine arabinoside and mitoxantrone for adults with newly diagnosed, poor-risk acute myelogenous leukemia , 2012, Haematologica.

[22]  S. Zahler,et al.  Roscovitine blocks leukocyte extravasation by inhibition of cyclin‐dependent kinases 5 and 9 , 2011, British journal of pharmacology.

[23]  P. Mahajan,et al.  P276-00, a novel cyclin-dependent inhibitor induces G1-G2 arrest, shows antitumor activity on cisplatin-resistant cells and significant in vivo efficacy in tumor models , 2007, Molecular Cancer Therapeutics.

[24]  M. de Silva,et al.  Discovery and SAR of novel pyrazolo[1,5-a]pyrimidines as inhibitors of CDK9. , 2015, Bioorganic & medicinal chemistry.

[25]  C. Scott,et al.  The BH3 mimetic ABT-737 targets selective Bcl-2 proteins and efficiently induces apoptosis via Bak/Bax if Mcl-1 is neutralized. , 2006, Cancer cell.

[26]  John Calvin Reed,et al.  Elevated expression of the apoptotic regulator Mcl-1 at the time of leukemic relapse. , 1998, Blood.

[27]  Erinna F. Lee,et al.  Anti-apoptotic Mcl-1 is essential for the development and sustained growth of acute myeloid leukemia. , 2012, Genes & development.

[28]  S. Grant,et al.  Orphan drug designation for pracinostat, volasertib and alvocidib in AML. , 2014, Leukemia research.

[29]  S. Emanuel,et al.  Design, synthesis, and evaluation of 3,4-disubstituted pyrazole analogues as anti-tumor CDK inhibitors. , 2007, Bioorganic & medicinal chemistry letters.

[30]  Sean Parkin,et al.  Alkaloids from the antarctic sponge Kirkpatrickia varialosa. , 1994 .

[31]  Cai-Guang Yang,et al.  Synthesis of indolylpyrimidines VIA cross-coupling of indolylboronic acid with chloropyrimidines: facile synthesis of meridlanin D , 2000 .

[32]  Michael W. Parker,et al.  Targeting acute myeloid leukemia by dual inhibition of PI3K signaling and Cdk9-mediated Mcl-1 transcription. , 2013, Blood.

[33]  H. Husum,et al.  Antimanic efficacy of retigabine in a proposed mouse model of bipolar disorder , 2010, Behavioural Brain Research.

[34]  D. M. Andrews,et al.  The discovery of AZD5597, a potent imidazole pyrimidine amide CDK inhibitor suitable for intravenous dosing. , 2008, Bioorganic & medicinal chemistry letters.

[35]  E. Lees,et al.  Discovery of Dinaciclib (SCH 727965): A Potent and Selective Inhibitor of Cyclin-Dependent Kinases. , 2010, ACS medicinal chemistry letters.

[36]  U. Rix,et al.  Chemoproteomics Reveals Novel Protein and Lipid Kinase Targets of Clinical CDK4/6 Inhibitors in Lung Cancer. , 2015, ACS chemical biology.

[37]  Chaoxin Hu,et al.  Combined Inhibition of Cyclin-Dependent Kinases (Dinaciclib) and AKT (MK-2206) Blocks Pancreatic Tumor Growth and Metastases in Patient-Derived Xenograft Models , 2015, Molecular Cancer Therapeutics.

[38]  P. Lienau,et al.  BAY 1000394, a Novel Cyclin-Dependent Kinase Inhibitor, with Potent Antitumor Activity in Mono- and in Combination Treatment upon Oral Application , 2012, Molecular Cancer Therapeutics.

[39]  M. Noble,et al.  The CDK9 C-helix Exhibits Conformational Plasticity That May Explain the Selectivity of CAN508 , 2012, ACS chemical biology.

[40]  Malini Guha,et al.  Cyclin-dependent kinase inhibitors move into Phase III , 2012, Nature Reviews Drug Discovery.

[41]  Anna Vulpetti,et al.  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 2. Lead optimization. , 2005, Journal of medicinal chemistry.

[42]  M. Mathews,et al.  Three RNA Polymerase II Carboxyl-terminal Domain Kinases Display Distinct Substrate Preferences* , 2001, The Journal of Biological Chemistry.

[43]  S. Singer,et al.  The Cyclin-Dependent Kinase Inhibitor Flavopiridol Potentiates Doxorubicin Efficacy in Advanced Sarcomas: Preclinical Investigations and Results of a Phase I Dose-Escalation Clinical Trial , 2012, Clinical Cancer Research.

[44]  Darjus F. Tschaharganeh,et al.  CDK9-mediated transcription elongation is required for MYC addiction in hepatocellular carcinoma , 2014, Genes & development.

[45]  A. Tefferi,et al.  Going beyond 7 + 3 regimens in the treatment of adult acute myeloid leukemia. , 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[46]  Chao Zhang,et al.  TFIIH-Associated Cdk7 Kinase Functions in Phosphorylation of C-Terminal Domain Ser7 Residues, Promoter-Proximal Pausing, and Termination by RNA Polymerase II , 2009, Molecular and Cellular Biology.

[47]  G. Jameson,et al.  Alkaloids from the antarctic sponge Kirkpatrickia varialosa. Part 2: Variolin A and N(3′)-methyl tetrahydrovariolin B , 1994 .

[48]  Samir Mehndiratta,et al.  Purine Analogues as Kinase Inhibitors: A Review. , 2015, Recent patents on anti-cancer drug discovery.

[49]  N. Cordes,et al.  The impact of CDK9 on radiosensitivity, DNA damage repair and cell cycling of HNSCC cancer cells. , 2016, International journal of oncology.

[50]  M. Grever,et al.  Flavopiridol (L86-8275): selective antitumor activity in vitro and activity in vivo for prostate carcinoma cells. , 1997, Clinical cancer research : an official journal of the American Association for Cancer Research.

[51]  E. Sausville,et al.  Flavopiridol Inhibits P-TEFb and Blocks HIV-1 Replication* , 2000, The Journal of Biological Chemistry.

[52]  D. W. Fry,et al.  Discovery of a potent and selective inhibitor of cyclin-dependent kinase 4/6. , 2005, Journal of medicinal chemistry.

[53]  A. Barker,et al.  AZD5438, a potent oral inhibitor of cyclin-dependent kinases 1, 2, and 9, leads to pharmacodynamic changes and potent antitumor effects in human tumor xenografts , 2009, Molecular Cancer Therapeutics.

[54]  J. Lyons,et al.  Biological characterization of AT 7519 , a small-molecule inhibitor of cyclin-dependent kinases , in human tumor cell lines , 2009 .

[55]  J. Testa,et al.  Cyclin T2A Gene Maps on Human Chromosome 2q21 , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[56]  Dirk Eick,et al.  TFIIH kinase places bivalent marks on the carboxy-terminal domain of RNA polymerase II. , 2009, Molecular cell.

[57]  J. Milton,et al.  Identification of multiple cyclin subunits of human P-TEFb. , 1998, Genes & development.

[58]  P. Schultz,et al.  Synthesis and application of functionally diverse 2,6,9-trisubstituted purine libraries as CDK inhibitors. , 1999, Chemistry & biology.

[59]  D. Eick,et al.  The structure and substrate specificity of human Cdk12/Cyclin K , 2014, Nature Communications.

[60]  S. Zahler,et al.  Characterization of a Pyrazolo[4,3‐d]pyrimidine Inhibitor of Cyclin‐Dependent Kinases 2 and 5 and Aurora A With Pro‐Apoptotic and Anti‐Angiogenic Activity In Vitro , 2015, Chemical biology & drug design.

[61]  P. Fischer,et al.  Synthesis, structure-activity relationship and biological evaluation of 2,4,5-trisubstituted pyrimidine CDK inhibitors as potential anti-tumour agents. , 2013, European journal of medicinal chemistry.

[62]  D. Chen,et al.  Requirement for a Kinase-specific Chaperone Pathway in the Production of a Cdk9/Cyclin T1 Heterodimer Responsible for P-TEFb-mediated Tat Stimulation of HIV-1 Transcription* , 2000, The Journal of Biological Chemistry.

[63]  E. Lees,et al.  Dinaciclib (SCH 727965), a Novel and Potent Cyclin-Dependent Kinase Inhibitor , 2010, Molecular Cancer Therapeutics.

[64]  J. Snyder,et al.  A novel pyrazolo[1,5-a]pyrimidine is a potent inhibitor of cyclin-dependent protein kinases 1, 2, and 9, which demonstrates antitumor effects in human tumor xenografts following oral administration. , 2010, Journal of medicinal chemistry.

[65]  A. Rice,et al.  Phosphatase PPM1A Regulates Phosphorylation of Thr-186 in the Cdk9 T-loop* , 2008, Journal of Biological Chemistry.

[66]  L. Meijer,et al.  Meriolins (3-(pyrimidin-4-yl)-7-azaindoles): synthesis, kinase inhibitory activity, cellular effects, and structure of a CDK2/cyclin A/meriolin complex. , 2008, Journal of medicinal chemistry.

[67]  Amit P. Sheth,et al.  RNAP II CTD Phosphorylated on Threonine-4 Is Required for Histone mRNA 3′ End Processing , 2011, Science.

[68]  S H Kim,et al.  Inhibition of cyclin-dependent kinases by purine analogues: crystal structure of human cdk2 complexed with roscovitine. , 1997, European journal of biochemistry.

[69]  E. Sausville,et al.  Alteration of the phosphorylation state of p34cdc2 kinase by the flavone L86-8275 in breast carcinoma cells. Correlation with decreased H1 kinase activity. , 1993, Biochemical pharmacology.

[70]  Soumya Lipsa Rath,et al.  Molecular Basis of Differential Selectivity of Cyclobutyl-Substituted Imidazole Inhibitors against CDKs: Insights for Rational Drug Design , 2013, PloS one.

[71]  Su-Ying Wu,et al.  Discovery of a novel family of CDK inhibitors with the program LIDAEUS: structural basis for ligand-induced disordering of the activation loop. , 2003, Structure.

[72]  O. Bensaude,et al.  Retrovirology BioMed Central , 2006 .

[73]  L. Meijer,et al.  CDK Inhibitors Roscovitine and CR8 Trigger Mcl-1 Down-Regulation and Apoptotic Cell Death in Neuroblastoma Cells. , 2010, Genes & cancer.

[74]  K. Joshi,et al.  Cyclin-dependent kinase inhibitor, P276-00 induces apoptosis in multiple myeloma cells by inhibition of Cdk9-T1 and RNA polymerase II-dependent transcription. , 2011, Leukemia research.

[75]  A. Senderowicz,et al.  Small molecule modulators of cyclin-dependent kinases for cancer therapy , 2000, Oncogene.

[76]  L. Milas,et al.  Inhibition of P-TEFb by DRB suppresses SIRT1/CK2α pathway and enhances radiosensitivity of human cancer cells. , 2014, Anticancer research.

[77]  J. Ahearn,et al.  A unique structure at the carboxyl terminus of the largest subunit of eukaryotic RNA polymerase II. , 1985, Proceedings of the National Academy of Sciences of the United States of America.

[78]  B. Rollins,et al.  A phase II trial of the cyclin-dependent kinase inhibitor flavopiridol in patients with previously untreated stage IV non-small cell lung cancer. , 2001, Clinical cancer research : an official journal of the American Association for Cancer Research.

[79]  M. El-Bahrawy,et al.  Selective CDK9 inhibition overcomes TRAIL resistance by concomitant suppression of cFlip and Mcl-1 , 2013, Cell Death and Differentiation.

[80]  E. Wiemer,et al.  Phase I Study of RGB-286638, A Novel, Multitargeted Cyclin-Dependent Kinase Inhibitor in Patients with Solid Tumors , 2014, Clinical Cancer Research.

[81]  J. Miguel,et al.  Antimyeloma Action of the Multikinase Inhibitor TG02 , 2010 .

[82]  T. Rana,et al.  Identification of Flavopiridol Analogues that Selectively Inhibit Positive Transcription Elongation Factor (P‐TEFb) and Block HIV‐1 Replication , 2009, Chembiochem : a European journal of chemical biology.

[83]  Shudong Wang,et al.  Synthesis and biological evaluation of imidazo[4,5-b]pyridine and 4-heteroaryl-pyrimidine derivatives as anti-cancer agents. , 2012, European journal of medicinal chemistry.

[84]  N. Meanwell.  Synopsis of some recent tactical application of bioisosteres in drug design. , 2011, Journal of medicinal chemistry.

[85]  Tamás Kiss,et al.  7SK small nuclear RNA binds to and inhibits the activity of CDK9/cyclin T complexes , 2001, Nature.

[86]  M. Noble,et al.  Comparative Structural and Functional Studies of 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidine-5-carbonitrile CDK9 Inhibitors Suggest the Basis for Isotype Selectivity , 2012, Journal of medicinal chemistry.

[87]  G. Shapiro,et al.  AZ703, an imidazo[1,2-a]pyridine inhibitor of cyclin-dependent kinases 1 and 2, induces E2F-1-dependent apoptosis enhanced by depletion of cyclin-dependent kinase 9. , 2006, Cancer research.

[88]  A. Natarajan,et al.  Perturbing pro-survival proteins using quinoxaline derivatives: a structure-activity relationship study. , 2012, Bioorganic & medicinal chemistry.

[89]  Paul G Wyatt,et al.  Identification of N-(4-piperidinyl)-4-(2,6-dichlorobenzoylamino)-1H-pyrazole-3-carboxamide (AT7519), a novel cyclin dependent kinase inhibitor using fragment-based X-ray crystallography and structure based drug design. , 2008, Journal of medicinal chemistry.

[90]  P. Molina,et al.  Synthetic studies towards the 2-aminopyrimidine alkaloids variolins and meridianins from marine origin , 2000 .

[91]  J. Blow,et al.  Inhibition of cyclin-dependent kinases by purine analogues. , 1994, European journal of biochemistry.

[92]  Peter M Fischer,et al.  Discovery and characterization of 2-anilino-4- (thiazol-5-yl)pyrimidine transcriptional CDK inhibitors as anticancer agents. , 2010, Chemistry & biology.

[93]  E. Sausville,et al.  Growth inhibition with reversible cell cycle arrest of carcinoma cells by flavone L86-8275. , 1992, Journal of the National Cancer Institute.

[94]  M. Clausen,et al.  FDA-approved small-molecule kinase inhibitors. , 2015, Trends in pharmacological sciences.

[95]  Gennady M Verkhivker,et al.  AG-024322 is a potent and selective multi-targeted CDK inhibitor with broad spectrum anti-proliferative activity , 2005 .

[96]  Z. Obradovic,et al.  Selective control of gene expression by CDK9 in human cells , 2010, Journal of cellular physiology.

[97]  L. Donehower,et al.  55K isoform of CDK9 associates with Ku70 and is involved in DNA repair. , 2010, Biochemical and biophysical research communications.

[98]  Yi Chen,et al.  Targeting RNA transcription and translation in ovarian cancer cells with pharmacological inhibitor CDKI-73 , 2014, Oncotarget.

[99]  M. Noble,et al.  Substituted 4-(Thiazol-5-yl)-2-(phenylamino)pyrimidines Are Highly Active CDK9 Inhibitors: Synthesis, X-ray Crystal Structures, Structure–Activity Relationship, and Anticancer Activities , 2013, Journal of Medicinal Chemistry.

[100]  Andrzej Kudlicki,et al.  Systematic Determination of Human Cyclin Dependent Kinase (CDK)-9 Interactome Identifies Novel Functions in RNA Splicing Mediated by the DEAD Box (DDX)-5/17 RNA Helicases* , 2015, Molecular & Cellular Proteomics.

[101]  Á. Gyuris,et al.  Novel, selective CDK9 inhibitors for the treatment of HIV infection. , 2011, Current medicinal chemistry.

[102]  M. Geyer,et al.  Serine-7 but not serine-5 phosphorylation primes RNA polymerase II CTD for P-TEFb recognition , 2012, Nature Communications.

[103]  X. Graña,et al.  CDK9 inhibition strategy defines distinct sets of target genes , 2014, BMC Research Notes.

[104]  Dirk Eick,et al.  Transcribing RNA Polymerase II Is Phosphorylated at CTD Residue Serine-7 , 2007, Science.

[105]  D. Lane,et al.  Structural determinants of CDK4 inhibition and design of selective ATP competitive inhibitors. , 2004, Chemistry & biology.

[106]  P. Fischer,et al.  4-arylazo-3,5-diamino-1H-pyrazole CDK inhibitors: SAR study, crystal structure in complex with CDK2, selectivity, and cellular effects. , 2006, Journal of medicinal chemistry.

[107]  M. Arkin,et al.  SNS-032 is a potent and selective CDK 2, 7 and 9 inhibitor that drives target modulation in patient samples , 2009, Cancer Chemotherapy and Pharmacology.

[108]  G. Rosner,et al.  Randomized multicenter phase II study of flavopiridol (alvocidib), cytarabine, and mitoxantrone (FLAM) versus cytarabine/daunorubicin (7+3) in newly diagnosed acute myeloid leukemia , 2015, Haematologica.

[109]  Chao Zhang,et al.  Cyclin-dependent kinase control of the initiation-to-elongation switch of RNA polymerase II , 2012, Nature Structural &Molecular Biology.

[110]  S H Kim,et al.  Exploiting chemical libraries, structure, and genomics in the search for kinase inhibitors. , 1998, Science.

[111]  A. De Luca,et al.  Pattern of Expression of Cyclin T1 in Human Tissues , 2001, The journal of histochemistry and cytochemistry : official journal of the Histochemistry Society.

[112]  S. Jain,et al.  Cyclin-dependent kinase inhibition by flavoalkaloids. , 2012, Mini reviews in medicinal chemistry.

[113]  A. Giordano,et al.  Cell cycle kinases as therapeutic targets for cancer , 2009, Nature Reviews Drug Discovery.

[114]  S. Nekhai,et al.  Regulation of CDK9 Activity by Phosphorylation and Dephosphorylation , 2014, BioMed research international.

[115]  P. Dent,et al.  Characterization of Cdk9(55) and differential regulation of two Cdk9 isoforms. , 2005, Gene.

[116]  P. Iversen,et al.  Preclinical characterization of the CDK4/6 inhibitor LY2835219: in-vivo cell cycle-dependent/independent anti-tumor activities alone/in combination with gemcitabine , 2014, Investigational New Drugs.

[117]  G. Shapiro.  Preclinical and Clinical Development of the Cyclin-Dependent Kinase Inhibitor Flavopiridol , 2004, Clinical Cancer Research.

[118]  S. Grant,et al.  Cyclin-dependent kinase inhibitor therapy for hematologic malignancies , 2013, Expert opinion on investigational drugs.

[119]  L. Puricelli,et al.  Indole alkaloids from the tunicate Aplidium meridianum. , 1998, Journal of natural products.

[120]  A. Baldi,et al.  Cyclin T: Three forms for different roles in physiological and pathological functions , 2003, Journal of cellular physiology.

[121]  P. Molina,et al.  Carbodiimide-mediated preparation of the tricyclic pyrido[3',2':4,5]pyrrolo[1,2-c]pyrimidine ring system and its application to the synthesis of the potent antitumoral marine alkaloid variolin B and analog. , 2003, The Journal of organic chemistry.

[122]  Thomas,et al.  Flavopiridol ( L 86-. 8275 ) : Selective Antitumor Activity in Vitro and Activity in Vivo for Prostate Carcinoma Cells , 2005 .

[123]  R. Pazdur,et al.  FDA Approval: Palbociclib for the Treatment of Postmenopausal Patients with Estrogen Receptor–Positive, HER2-Negative Metastatic Breast Cancer , 2015, Clinical Cancer Research.

[124]  D O Morgan,et al.  Cell cycle regulation of CDK2 activity by phosphorylation of Thr160 and Tyr15. , 1992, The EMBO journal.

[125]  F. Albericio,et al.  Total syntheses of variolin B and deoxyvariolin B. , 2003, The Journal of organic chemistry.

[126]  D. Price,et al.  Flavopiridol Inactivates P-TEFb and Blocks Most RNA Polymerase II Transcription in Vivo * , 2001, The Journal of Biological Chemistry.

[127]  S. Elledge,et al.  Human Cyclin K, a Novel RNA Polymerase II-Associated Cyclin Possessing Both Carboxy-Terminal Domain Kinase and Cdk-Activating Kinase Activity , 1998, Molecular and Cellular Biology.

[128]  L Meijer,et al.  CR8, a potent and selective, roscovitine-derived inhibitor of cyclin-dependent kinases , 2008, Oncogene.

[129]  Y. Shyr,et al.  Cyclin‐dependent kinase 9–cyclin K functions in the replication stress response , 2010, EMBO reports.

[130]  S. Joel,et al.  RNA synthesis block by 5,6-dichloro-1-β-D-ribofuranosylbenzimidazole (DRB) triggers p53-dependent apoptosis in human colon carcinoma cells , 1999, Oncogene.

[131]  E. Sausville,et al.  Flavopiridol induces G1 arrest with inhibition of cyclin-dependent kinase (CDK) 2 and CDK4 in human breast carcinoma cells. , 1996, Cancer research.

[132]  K. Joshi,et al.  P276-00, a cyclin-dependent kinase inhibitor, modulates cell cycle and induces apoptosis in vitro and in vivo in mantle cell lymphoma cell lines , 2012, Molecular Cancer.

[133]  E. Sausville,et al.  Down-regulation of cyclin D1 by transcriptional repression in MCF-7 human breast carcinoma cells induced by flavopiridol. , 1999, Cancer research.

[134]  Richard J. Jones,et al.  Sequential Flavopiridol, Cytosine Arabinoside, and Mitoxantrone: A Phase II Trial in Adults with Poor-Risk Acute Myelogenous Leukemia , 2007, Clinical Cancer Research.

[135]  T. Albert,et al.  Characterization of molecular and cellular functions of the cyclin‐dependent kinase CDK9 using a novel specific inhibitor , 2014, British journal of pharmacology.

[136]  K. Joshi,et al.  In vitro antitumor properties of a novel cyclin-dependent kinase inhibitor, P276-00 , 2007, Molecular Cancer Therapeutics.

[137]  K. Joshi,et al.  Abstract 3054: P1446A-05: a new oral cyclin-dependent kinase inhibitor with potent preclinical antitumor activity , 2012 .

[138]  C. Bloomfield,et al.  Treatment of acute myelocytic leukemia: a study by cancer and leukemia group B. , 1981, Blood.

[139]  Peter M Fischer,et al.  Cyclin-dependent kinase 9: a key transcriptional regulator and potential drug target in oncology, virology and cardiology. , 2008, Trends in pharmacological sciences.

[140]  A. Osnowski,et al.  2-Anilino-4-(thiazol-5-yl)pyrimidine CDK inhibitors: synthesis, SAR analysis, X-ray crystallography, and biological activity. , 2004, Journal of medicinal chemistry.

[141]  G. Schwartz,et al.  Phase I study of the cyclin-dependent kinase inhibitor flavopiridol in combination with paclitaxel in patients with advanced solid tumors. , 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[142]  Jonathan C. Morris,et al.  Total synthesis of variolin B , 2001 .

[143]  L. Johnson,et al.  The structure of P‐TEFb (CDK9/cyclin T1), its complex with flavopiridol and regulation by phosphorylation , 2008, The EMBO journal.

[144]  K. Anderson,et al.  Small Molecule Multi-Targeted Kinase Inhibitor RGB-286638 Triggers P53-Dependent and -Independent Anti-Multiple Myeloma Activity through Inhibition of Transcriptional CDKs , 2013, Leukemia.

[145]  Anna Vulpetti,et al.  3-Aminopyrazole inhibitors of CDK2/cyclin A as antitumor agents. 1. Lead finding. , 2004, Journal of medicinal chemistry.

[146]  J. Lyons,et al.  Biological characterization of AT7519, a small-molecule inhibitor of cyclin-dependent kinases, in human tumor cell lines , 2009, Molecular Cancer Therapeutics.

[147]  Guoying Yu,et al.  Compensatory induction of MYC expression by sustained CDK9 inhibition via a BRD4-dependent mechanism , 2015, eLife.

[148]  H. Hirai,et al.  Identification of potent 5-pyrimidinyl-2-aminothiazole CDK4, 6 inhibitors with significant selectivity over CDK1, 2, 5, 7, and 9. , 2006, Bioorganic & medicinal chemistry letters.

[149]  L. Meijer,et al.  Meriolins, a new class of cell death inducing kinase inhibitors with enhanced selectivity for cyclin-dependent kinases. , 2007, Cancer research.

[150]  S. Cory,et al.  ABT-199, a new Bcl-2-specific BH3 mimetic, has in vivo efficacy against aggressive Myc-driven mouse lymphomas without provoking thrombocytopenia. , 2013, Blood.

[151]  Theonie Anastassiadis,et al.  Comprehensive assay of kinase catalytic activity reveals features of kinase inhibitor selectivity , 2011, Nature biotechnology.

[152]  Jeffrey A Jones,et al.  Dinaciclib is a Novel Cyclin Dependent Kinase Inhibitor with Significant Clinical Activity in Relapsed and Refractory Chronic Lymphocytic Leukemia , 2015, Leukemia.

[153]  S H Kim,et al.  Structural basis for specificity and potency of a flavonoid inhibitor of human CDK2, a cell cycle kinase. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[154]  A. Rice,et al.  Cdk9 T‐loop phosphorylation is regulated by the calcium signaling pathway , 2012, Journal of cellular physiology.

[155]  Dongmei Cheng,et al.  Analysis of the Large Inactive P-TEFb Complex Indicates That It Contains One 7SK Molecule, a Dimer of HEXIM1 or HEXIM2, and Two P-TEFb Molecules Containing Cdk9 Phosphorylated at Threonine 186* , 2005, Journal of Biological Chemistry.

[156]  Cai-Guang Yang,et al.  Synthesis of Indolylpyrimidines via Cross-Coupling of Indolylboronic Acid with Chloropyrimidines: Facile Synthesis of Meridianin D. , 2000 .

[157]  L. Meijer,et al.  Synthesis, anti-inflammatory, analgesic and kinase (CDK-1, CDK-5 and GSK-3) inhibition activity evaluation of benzimidazole/benzoxazole derivatives and some Schiff's bases. , 2006, Bioorganic & medicinal chemistry.

[158]  G. Kéri,et al.  Synthesis and evaluation of phosphorus containing, specific CDK9/CycT1 inhibitors. , 2014, Journal of medicinal chemistry.